Review articleThe relationship between progestin hormonal contraception and depression: a systematic review
Introduction
Sexually active women of reproductive age who want to prevent pregnancy need reliable contraceptive options. Decisions about which method to choose may involve factors such as efficacy, medical problems, previous experiences with side effects or failures, or concerns about imperfect compliance. Due to the risks or side effects of estrogen, many women choose a hormonal contraceptive that is formulated only with progestin. Even with limited progestin exposure, concerns exist about side effects including weight gain, acne, mood changes and depression. Depression side effects of progestin contraception have been stressed in the lay press and are common patient concerns [1], [2]. Depression is also a concern for women considering hormonal contraception due to female population prevalence. The major depression lifetime prevalence for US women is 7.4/100, twice that of men [3]. Concerns about progestin's influence on mood are based on clinical experience and basic science research [4], [5].
Concerns about progestin-related depression effects also arise from early clinical data on depot medroxyprogesterone acetate (DMPA), which was approved for use as a long-acting contraceptive in 1992 by the Food and Drug Administration (FDA). The package labeling stated that women with depression should be observed carefully, and additional administration should not be performed if depression recurred. This concern was based on FDA clinical data showing that 1.5% of 4200 users reported depression and 0.5% discontinued their use of DMPA for this reason [6]. Since then, many studies have sought an answer to whether DMPA may cause depression.
The relationship between progestin-only contraceptives and depression remains unclear. This study aims to systematically review the medical literature regarding this relationship, additionally including generalized and postpartum depression, as well as adolescents.
Section snippets
Methods
We conducted this systematic review using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [7]. Prior to conducting our literature review, we identified the following questions to guide our search:
- 1.
Is there an association or causative link between progestin-only hormonal contraception and depression effects in human females?
- 2.
Does the type of progestin or route of administration influence such an association?
- 3.
Are there certain populations (such as adolescents,
Study selection
Our search used multiple title and abstract searches plus PubMed MESH search terms including “medroxyprogesterone depression” with 155 abstracts, “levonorgestrel depression” with 80 abstracts, “norethindrone depression” with 126 abstracts, “etonorgestrel depression” with 8 abstracts, “Progestin [AND] depression [AND] contraception” with 190 abstracts and “progestin [AND] postpartum depression” with 78 abstracts. This initially yielded 2305 citations and, once exclusion criteria were applied,
Conclusions
In summary, it is difficult to draw firm conclusions about the relationship between progestin-only hormonal contraception and depression. The data thus far do not support a clear, general relationship between progestin contraceptives and depression scores or incident depression diagnoses.
Several limitations exist in assessing the link between progestin-only hormonal contraception and depression. The trials that use validated measures of depression symptoms use a variety of scales, some of which
Funding
This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.
References (40)
- et al.
The progesterone metabolite allopregnanolone potentiates GABA(a) receptor-mediated inhibition of 5-HT neuronal activity
Eur Neuropsychopharmacol
(2007) - et al.
A rodent model of premenstrual dysphoria: progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants
Behav Brain Res
(2012) - et al.
Depressive symptoms and depo-Provera
Contraception
(1998) - et al.
Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microgram oral contraceptive pills
Am J Obstet Gynecol
(2008) - et al.
Depressive symptoms in users and non-users of depot medroxyprogesterone acetate
Contraception
(2000) - et al.
Depression in users of depo-medroxyprogesterone acetate
Contraception
(1995) - et al.
Depot medroxyprogesterone acetate: patterns of use and reasons for discontinuation
(1997) - et al.
Depressive symptoms and Norplant contraceptive implants
Contraception
(1998) - et al.
Contraception with two levonorgestrel rod implants
Contraception
(1998) - et al.
Adolescents and Norplant: preliminary findings of side effects
J Adolesc Health
(1995)
Implanon users are less likely to be satisfied with their contraception after 6 months than IUD users
Contraception
Insertion and 3-year follow-up experience of 372 etonorgestrel subdermal contraceptive implants by family physicians in Granada, Spain
Contraception
Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia
Contraception
Levonorgestrel contraceptive implants in female patients 14 to 21 years old
Mayo Clin Proc
The effects of steroidal contraceptives on the well-being and sexuality of women: a double-blind, placebo-controlled, two-centre study of combined and progestin-only methods
Contraception
Effect of depot medroxyprogesterone acetate on postpartum depression
Contraception
The timing of Norplant insertion and postpartum depression in teenagers
J Adolesc Health
Mood changes in adolescents using depot-medroxyprogesterone acetate for contraception: a prospective study
J Pediatr Adolesc Gynecol
Depo-Provera in adolescents: effects of early second injection or prior oral contraception
J Adolesc Health
Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression
Psychoneuroendocrinology
Cited by (73)
The link between daily affective complexity and anxiety is altered by oral contraceptive use
2024, International Journal of PsychophysiologyA mouse model of oral contraceptive exposure: Depression, motivation, and the stress response
2024, Hormones and BehaviorSymptoms of mental disorders and oral contraception use: A systematic review and meta-analysis
2024, Frontiers in NeuroendocrinologyLevonorgestrel intrauterine device and depression: A Swedish register-based cohort study
2023, International Journal of PsychophysiologyThe menstrual cycle and mental health: a focus on mood and anxiety
2023, Encyclopedia of Mental Health, Third Edition: Volume 1-3Hormonal contraceptive influences on cognition and psychopathology: Past methods, present inferences, and future directions
2022, Frontiers in NeuroendocrinologyCitation Excerpt :These gender differences emerge around puberty, and so, there has long been speculation that sex, including ovarian, hormones are contributors to the differences. In this section, the relevant literature on HCs and psychopathology will be summarized, relaying conclusions from past work and reviews (Böttcher et al., 2012; Brønnick et al., 2020; Fruzzetti & Fidecicchi, 2020; Laird et al., 2019; Li & Graham, 2017; Montoya & Bos, 2017; Robakis et al., 2019; Schaffir et al., 2016; Worly et al., 2018), while highlighting field-shifting findings and novel inferences, especially those associated with study methods that can provide insights for future work. Research on emotion will only be considered when it is especially noteworthy, given that it is a multidetermined mechanism underlying depression and anxiety and is inconclusively linked to HCs (see Barrett, 2006; Montoya & Bos, 2017).